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Introduction
Metabolite identification studies within drug discovery are generally used to identify metabolically labile sites on chemical structures, human metabolites which may not be represented in the toxicological species, active metabolites or potential reactive/toxic metabolites, which are of concern for the pharmaceutical industry 1 2 3 . These discovery studies are conducted in vitro and generally involve incubation of a test compound in hepatocytes or microsomes, which mimic the most prevalent metabolic processes occurring in the liver. Typically, samples are taken from the test compound incubates, then added to acetonitrile to quench the reaction at t=0 min (control) and at a terminal time point (usually 30-60 min). Subsequently, samples are analysed on high resolution accurate mass UHPLC-MS/MS systems and comparison of the t=0 min vs the t=60 min samples enables easier identification of metabolites from endogenous components. The analysis can be both challenging and time consuming even when identifying only a small number of metabolites.
Often the data has to be generated and reported quickly to impact the chemistry design and unusual unexpected metabolites/products are not fully investigated due to time constraints.
Such products can occasionally be formed through reactive or toxic metabolites.
Here we present an unusual finding from an in vitro metabolite identification study of compound AZX, a representative compound from a structurally related chemical series, in human liver microsomes (HLM). AZX ( Figure 1 ) generated several metabolites in HLM that were predominantly oxidative biotransformation products, which highlighted the hydroxyacetamide side chain as a major site of metabolism for the molecule. Additionally, two unexpected methanol adduct products were detected with different retention times yet identical mass. Methanol adducts are fairly common in mass spectrometry and are normally identified as analytical artefacts of the parent drug, generated during the positive ion electrospray ionisation process. Pozo et al. (2007) 4 reported the analysis of steroids using 5 electrospray generated adducts such as [M + MeOH] or [M+ Na +MeOH]. However, in this case AZX reacted with methanol in the mobile phase prior to the mass spectrometry ionisation process. The methanol adducts not only eluted at a different retention time to the parent drug, but two chromatographically separate methanol adduct peaks were observed, indicating the presence of isomers. These adducts were not detected in either the t=0 control samples or when acquired with acetonitrile as the mobile phase. This inferred a metabolic transformation to a reactive metabolite formed in the t=60 sample, which subsequently generated the methanol adducts on injection onto the UHPLC column. The formation of these methanol adducts is subject to further investigation in this paper. 
Materials and Methods

Chemicals
AZX stock solution
Solid AZX was dissolved in dimethyl sulfoxide to a concentration of 10 mM
In vitro incubation spiking solution
AZX dimethyl sulfoxide stock was diluted with 0.1 M potassium phosphate buffer (pH 7.4) to a concentration of 2 mM. This solution was then spiked into the in vitro incubation at 1:100 (v/v) to give a final concentration in the incubation of 20 uM.
In vitro incubation experimental methods
Three separate incubations were performed with parent compound (AZX):
A) AZX was incubated at 20 μM with HLM (2 mg protein/mL, BD-Gentest 150 donor ultrapool) in 0.1 M potassium phosphate buffer at pH 7.4 and 2.5 mM Nicotinamide adenine dinucleotide phosphate (NADPH) at 37 °C. An aliquot was removed after 0 min (control) and 7 B) AZX was incubated as described in A, but with 10 mM methoxyamine trapping agent
added. An aliquot was removed after 60 minutes and the reaction stopped by the addition of ice cold MeCN (1:1, v/v).
C) AZX was incubated as described in A. An aliquot was removed after 60 min and the reaction stopped by the addition of ice cold MeCN (1:1, v/v) containing 10 mM methoxyamine. The extract was then incubated for a further 10 min at 37°C.
D)
AZX was incubated as described in A, but with 10 mM GSH trapping agent added. An aliquot was removed after 60 minutes and the reaction stopped by the addition of ice cold
Sample preparation -analytical incubation
Quenched incubates were centrifuged at ca. 3000g for 15 min, and the supernatant retained.
An aliquot of the the supernatant was transferred to a Waters HPLC 2 mL vial and diluted 1:3 (v/v) with ultra purified distilled water prior to the LC-MS analyses.
Profiling and Structural characterisation of metabolites by UPLC-LTQ-Orbitrap Mass spectrometry
Accurate mass structural characterisation work was acquired on a LTQ Orbitrap XL (Thermo Fisher Scientific, Bremen, Germany) connected to a Waters Acquity UPLCTM system. The
Waters Acquity system (Waters, Milford, MA, USA) consisted of a binary UPLC Pump, column oven, a sample manager and a photodiode array detector. Separation was carried out on a Waters BEH C18 (100 x 2.1 mm, 1.7 µM) (Waters, Milford, MA, USA), preceded by a guard filter in a column oven at 50 ºC. LTQ and Orbitrap mass detectors were calibrated within one day of commencing the work using Proteomass LTQ/FT-Hybrid ESI positive mode calibration mix (Supelco, Bellefonte, USA).
Data Analysis
9
Mass spectrometric data were collected using Xcalibur version 2.1 (Thermo Fisher Scientific, Bremen, Germany). Components were identified as being derived from AZX by common fragments, isotopic pattern (Chlorine), UV absorbance and accurate mass. Comparisons with T=0 incubations were conducted to minimise the potential for false positives from system impurities and endogenous components.
Results
The initial full characterization of test compound with accurate mass MS/MS fragmentation often allows structural motifs and characteristic fragment ions to be identified, which assist the elucidation of the metabolite structures. MS/MS fragmentation experiments were undertaken in positive ion for the structural characterisation of metabolites or chemical addition products. All accurate mass measurements including the MS/MS fragmentation were within ±3ppm of the theoretical accurate mass.
Structural characterization of AZX by LC-MS/MS
In By accurate mass it was confirmed this addition was one oxygen atom and loss of two hydrogens to the methylpiperidylethanone group. Detection of the methylpiperazine fragment (m/z 98.0963, also observed in AZX) confirmed the piperazine ring was unchanged and the biotransformation had occurred on the hydroxyacetamide side chain. The product ion m/z 126.0911 represents loss of CO 2 from the hydroxyacetyl side chain, which is consistent with an acid on the terminal side chain carbon.
Structural characterization of the hydrate product (+O) by LC-MS/MS
The hydrate metabolite was only detected at trace levels when methanol was used as a mobile phase eluent, but it was the predominant species when acetonitrile.was used Therefore the MS/MS spectra shown in Figure 3 
Structural characterization of the methoxyamine adduct by LC-MS/MS
In positive ion mode the methoxyamine adduct yielded a protonated molecular ion displaying 
Discussion
This study demonstrated that compound AZX on incubation with HLM generated a reactive aldehyde metabolite that subsequently formed two methanol adduct isomers (Figure 7 ). It is therefore prudent to identify compounds or structural moieties that form reactive aldehyde metabolites early in drug discovery to modify or change the chemistry and remove the liability. It is also important to note that AZX did not form an adduct in the HLM GSH trapping experiment, thus escaping detection from the early routine in-house reactive metabolite screen. Without the formation of the methanol adducts, the aldehyde may not have been identified until much later in drug discovery.
In conclusion, analytical artefacts (such as methanol adducts) are not desired and can confuse the analysis or lead to misinterpretation. However, here we presented an example where the methanol adducts were diagnostic and pivotal in identifying a reactive aldehyde metabolite, thus highlighting the importance of fully investigating any unusual adducts observed in metabolite identification studies.
Whilst the reactive aldehyde metabolite could be proposed from the detection of methanol adducts, the hydrate metabolite is simply addition of Oxygen (+16 amu) to parent compound, which is a very common biotransformation reaction. If the initial analysis had been undertaken in acetonitrile it is likely that the hydrate would have been reported as a simple hydroxylated metabolite and the reactive aldehyde liability for the chemical series missed.
In summary, the proposed bioactivation of AZX occurred via the reactive aldehyde intermediate, which It is important to note that readily reacted with methanol to form a pair of isomeric hemiacetal methanol adducts. The reactive aldehyde metabolite was not detected and could not be structurally characterized directly, in acidified methanol the equilibrium favoured the methanol adduct and in acidified acetonitrile it favoured the hydrate.
The aldehyde did not form an adduct with GSH, escaping detection in our conventional in vitro trapping screen, however, it was trapped with methoxyamine. A significant efficiency gain (>20 fold increase in yield of adduct) was observed when methoxyamine was added immediately post incubation over the traditional method, where methoxyamine is added pre incubation. 
